1Dabgiv 110 Tablet contains Dabigatran Etexilate, a direct thrombin inhibitor used as an oral anticoagulant. This medication plays a crucial role in preventing the formation of harmful blood clots in the body and is especially effective in managing and reducing the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation (a type of irregular heartbeat). It is also commonly prescribed for the prevention and treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), particularly after orthopedic surgeries such as hip or knee replacement.
Dabigatran works by inhibiting thrombin, an enzyme essential for the final step in the coagulation cascade, where fibrinogen is converted to fibrin to form clots. By directly blocking thrombin, Dabigatran prevents clot formation, making it an effective option in managing thromboembolic disorders.
One of the key advantages of Dabgiv 110 is its rapid onset of action and predictable pharmacokinetics, which eliminates the need for routine coagulation monitoring, unlike traditional anticoagulants such as warfarin. It also has fewer dietary restrictions and drug interactions, making it a convenient and reliable choice for long-term use.
The capsule formulation is designed to deliver the active ingredient effectively through the gastrointestinal tract. It is essential to swallow the capsule whole to maintain the integrity of the drug’s absorption. Crushing or chewing can increase the risk of bleeding due to rapid release.
Dabgiv 110 is typically taken twice daily, and dosage may vary based on the condition being treated, renal function, and individual patient response. It is important to maintain regular intake and not skip doses to ensure consistent blood-thinning activity.
Patients taking Dabigatran should be cautious of signs of bleeding (such as unusual bruising, prolonged bleeding, or blood in urine or stool) and report them immediately to their healthcare provider.